


2025 Endotoxin Testing Summit

Lyon, France - Agenda

Business Use Only



Mardi 24 juin 2025

Jour 1

Horaires	Sofitel Lyon Bellecour
> 09:00 – 09:30	Accueil & Bienvenue
> 09:30 – 10:00	Introduction du concept de plateforme analytique dans l'environnement QC afin de gagner en efficacité et en qualité. Raphael Vigan, Sanofi – Global Quality, Innovation & automation QC Project Leader
> 10:00 – 10:30	Initiative de la chaîne d'approvisionnement pharmaceutique – Pratiques éthiques et durables dans les tests d'endotoxines : Réduction de la dépendance au sang de Limule (présentation en anglais, à distance) Shahjahan Shaid, GSK, Head of novel analytical technologies
> 10:30 – 11:00	Pause
> 11:00 – 11:30	Les bénéfices d'avoir LONZA comme fournisseur de Services Greet De Cock, Lonza, Scientific Support Team
> 11:30 – 12:00	Compréhension et implication des interactions Endotoxines dans la chaîne de production et dans la formulation des produits. Sébastien Bonot, Guerbet, Global Microbiology & Sterility Assurance Manager
> 12:00 – 12:15	Session interactive
> 12:15 – 13:30	Déjeuner
> 13:30 – 14:15	Atelier 1 : Conseils et résolution de problèmes sur la méthode du facteur C recombinant (rFC)
> 14:15 – 15:00	Atelier 2 : Tests d'activation des monocytes (MAT)
> 15:00 – 15:15	Pause
> 15:15 – 16:00	Atelier 3 : MODA® - Logiciel de Gestion de Données en Environnement GMP
> 14:15 – 15:00	Atelier 4 : Automatisation des tests Endotoxines avec le système PyroTec® PRO
> 16:45 – 17:00	Session interactive
> 19:00 - 23:00	Dîner Croisière, networking et activités à bord



LONZA

Mercredi 25 juin 2025

Jour 2

Horaires	Sofitel Lyon Bellecour
> 09:00 – 09:15	Accueil & Bienvenue
> 09:15 – 09:45	Historique des Endotoxines / des Tests Endotoxines. Dernière mise à jour réglementaire (Ph. Eu.) sur les Pyrogènes, le MAT et les tests Endotoxines, y compris les futures évolutions. Thierry Bonnevey, Sanofi, Microbiology Analytical Expert, Analytical Science R&D
> 09:45 – 10:15	Mise en œuvre d'une nouvelle méthode de test d'activation des monocytes pour détecter et quantifier les pyrogènes. Mr Potiquet, Solvias, Principal Scientist
> 10:15 – 10:45	Pause
> 10:45 – 11:15	Stratégies pour les tests d'Endotoxines dans les formulations RNA-LNP (présentation en anglais) Dr. Mohamad Toutonji, Molgenium, GMP Consultant
> 11:15 – 11:45	Facteur rFC et ISO 14001 TBD
> 11:45 – 12:15	Session interactive
> 12:15 – 12:30	Clôture
> 12:30	Déjeuner

A photograph showing a man and a woman looking at a large horseshoe crab (Limulus) in a bowl. The man is on the right, wearing sunglasses on his head, and the woman is on the left. They are both smiling and looking at the crab. The background is slightly blurred, suggesting an outdoor setting.

LONZA



Thierry Bonnevey

Thierry Bonnevey has more than 25 years of experience in the field of microbiological quality control, acquired within the Sanofi Vaccine and has held various positions in this field both in industrial affairs and in R&D. He is a member of the European Pharmacopoeia Expert Group EDQM within Group 1 Microbiology (since 2016), the Bacterial Endotoxins Working Group (WP BET) since 2017 and the Mycoplasma Working Group (WP MYC) since 2018. Finally, he is part of the board of the French association A3P since 2017.



TBD



Sébastien Bonot

Attached to the Guerbet quality department, Sébastien Bonot leads microbiology and sterility assurance across all department activities: production of active ingredients (API sites), formulation and packaging of medicines (F&F sites) and production of medical devices.



Thibaut Potiquet, MSc

Thibaut Potiquet graduated a MSc in Microbiology and Quality Assurance in co-operation with the University of Burgundy and AgroSup Dijon (Food engineering school) and has ten years of experience in QC Microbiology laboratories. He joined Solvias in 2017 as Head of Microbiology Laboratory and left the company in 2019 for two years to join Eurofins Eastern Microbiology Laboratory SAS as a Microbiology Expert member of the steering committee. He returned to Solvias in April 2021 as Head of Pyrogens Department and changed positions to be Principal Scientist Microbiology and Deputy of the QC Director (Microbiology and Physical-Chemistry) in September 2022.



Greet De Cock

Diplômée en biologie et biotechnologie, j'ai travaillé toute ma vie professionnelle dans un environnement de laboratoire. Près de 7 ans chez Lonza me permettent de combiner 2 passions, la science et les voyages. Pendant mon emploi chez Lonza, j'ai pu découvrir une grande partie de l'Europe tout en effectuant des services et en rencontrant uniquement des clients très intéressants et merveilleux.



Shahjahan Shaid

Dr. Shahjahan Shaid currently leads the team of Novel Analytical Technologies within the Global MSAT organization of GSK aimed at enabling the company strategy to introduce new analytical technologies which covers reduction of animal testing and animal derived materials by substituting them with state-of-the-art technologies. Shahjahan joined Novartis Vaccines, now GSK, in 2013 to lead and implement innovative technologies in the Quality Control of the company. Prior to that, he worked for diagnostics of zoonoses at the German Federal Health Robert Koch Institute. Shahjahan holds a PhD in Biology with a focus on immunology and host pathogen interaction and has experience in the pharmaceutical vaccine industry with an extensive knowledge of introducing novel assays in cGMP.



Dr. Mohamad Toutounji

Dr. Mohamad Toutounji is an independent pharmaceutical consultant with over six years of experience in CMC, QC, and regulatory affairs. He specializes in mRNA therapies, GMP compliance, and analytical method development. His work supports global regulatory submissions and the development of biologics, cell and gene therapies, and mRNA-based drug products.



Raphael Vigan

I hold a biochemistry engineering degree from the INSA School (Lyon, France) and a PhD in virology (King's College London) and after gaining experience in the pharmaceutical manufacturing industries (Octapharma & Baxter), I joined the QC department at Sanofi Pasteur in 2016. Until 2020, as a quality control manager, I ensured the control of Poliomyelitis, Rabies and Hepatitis A vaccines along with continuous improvement projects and the management of quality events. From July 2020 to April 2022, I led a dedicated QC team to allow the transfer of the analytical methods from the US to the MLE site for the new COVID vaccine. Since April 2022, I develop the QC Automation & digitalization roadmap to improve QC capacities by integrating current and new technologies. In this activity I support the overall Quality Control objectives and develop, implement, continuous improvement with projects supporting harmonization, simplification and improvement of business and operational practices for Quality Control.